Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2013

01-12-2013 | Research Article

RACK1 promoted the growth and migration of the cancer cells in the progression of esophageal squamous cell carcinoma

Authors: Fengqing Hu, Zhen Tao, Mingsong Wang, Guoqing Li, Yunjiao Zhang, Hong Zhong, Haibo Xiao, Xiao Xie, Mei Ju

Published in: Tumor Biology | Issue 6/2013

Login to get access

Abstract

Dysregulation of hedgehog signaling has been involved in esophageal squamous cell carcinoma (ESCC) by the mechanisms that are not fully understood. The receptor for activated protein kinase C (RACK1) is involved in the progression of multiple cancers. However, its expression and function in ESCC have not been investigated. Here, we found that the expression of RACK1 was upregulated in ESCC clinical samples. Moreover, over-expression of RACK1 in ESCC cells promoted cell proliferation and migration, while downregulation of RACK1 impaired the proliferation and migration of ESCC cells in vitro and in vivo. Mechanistically, RACK1 promoted the proliferation and migration of ESCC cells by activating hedgehog signaling. Taken together, our study suggested RACK1 might be an important therapeutic target in ESCC.
Literature
1.
2.
Rubin LL, Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov. 2006;5:1026–33.PubMedCrossRef
3.
Sasaki H, Hui C, Nakafuku M, Kondoh H. A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro. Development. 1997;124:1313–22.PubMed
4.
Xie J. Hedgehog signaling pathway: development of antagonists for cancer therapy. Curr Oncol Rep. 2008;10:107–13.PubMedCrossRef
5.
Lee SY, Han HS, Lee KY, et al. Sonic hedgehog expression in gastric cancer and gastric adenoma. Oncol Rep. 2007;17:1051–5.PubMed
6.
Karhadkar SS, Bova GS, Abdallah N, et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 2004;431:707–12.PubMedCrossRef
7.
Mori Y, Okumura T, Tsunoda S, Sakai Y, Shimada Y. Gli-1 expression is associated with lymph node metastasis and tumor progression in esophageal squamous cell carcinoma. Oncology. 2006;70:378–89.PubMedCrossRef
8.
Wang Z, Zhang B, Jiang L, et al. RACK1, an excellent predictor for poor clinical outcome in oral squamous carcinoma, similar to Ki67. Eur J Cancer. 2009;45:490–6.PubMedCrossRef
9.
Slager RE, Devasure JM, Pavlik JA, et al. RACK1, a PKC targeting protein, is exclusively localized to basal airway epithelial cells. J Histochem Cytochem. 2008;56:7–14.PubMedCrossRef
10.
Doan AT, Huttenlocher A. RACK1 regulates Src activity and modulates paxillin dynamics during cell migration. Exp Cell Res. 2007;313:2667–79.PubMedCrossRef
11.
Serrels B, Sandilands E, Serrels A, et al. A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarity. Curr Biol. 2010;20:1086–92.PubMedCrossRef
12.
Mamidipudi V, Dhillon NK, Parman T, et al. RACK1 inhibits colonic cell growth by regulating Src activity at cell cycle checkpoints. Oncogene. 2007;26:2914–24.PubMedCrossRef
13.
Wang F, Yamauchi M, Muramatsu M, et al. RACK1 Regulates VEGF/Flt1-mediated Cell Migration via Activation of a PI3K/Akt Pathway. J Biol Chem. 2011;286:9097–106.PubMedCrossRef
14.
Deng YZ, Yao F, Li JJ, et al. RACK1 Suppresses Gastric Tumorigenesis by Stabilizing beta-Catenin Destruction Complex. Gastroenterology. 2012;142:812–23.PubMedCrossRef
15.
Ma X, Chen K, Huang S, et al. Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis. 2005;26:1698–705.PubMedCrossRef
16.
Subauste MC, Ventura-Holman T, Du L, et al. RACK1 down-regulates levels of the pro-apoptotic protein Fem1b in apoptosis-resistant colon cancer cells. Cancer Biol Ther. 2009;8:2297–305.PubMed
17.
Cao XX, Xu JD, Xu JW, et al. RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo. Breast Cancer Res Treat. 2010;123:375–86.PubMedCrossRef
18.
Wang Z, Jiang L, Huang C, et al. Comparative proteomics approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma. Mol Cell Proteomics. 2008;7:1639–50.PubMedCrossRef
19.
Ishizuka T, Tanabe C, Sakamoto H, et al. Gene amplification profiling of esophageal squamous cell carcinomas by DNA array CGH. Biochem Biophys Res Commun. 2002;96:152–5.CrossRef
20.
Maesawa C, Tamura G, Iwaya T, et al. Mutations in the human homologue of the Drosophila patched gene in esophageal squamous cell carcinoma. Genes Chromosom Cancer. 1998;21:276–9.PubMedCrossRef
21.
Shi S, Deng YZ, Zhao JS, et al. RACK1 promotes non-small-cell lung cancer tumorigenicity through activating sonic hedgehog signaling pathway. J Biol Chem. 2012;287:7845–58.PubMedCrossRef
Metadata
Title
RACK1 promoted the growth and migration of the cancer cells in the progression of esophageal squamous cell carcinoma
Authors
Fengqing Hu
Zhen Tao
Mingsong Wang
Guoqing Li
Yunjiao Zhang
Hong Zhong
Haibo Xiao
Xiao Xie
Mei Ju
Publication date
01-12-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0977-7

Other articles of this Issue 6/2013

Tumor Biology 6/2013 Go to the issue

Research Article

Current evidences on IL1B polymorphisms and lung cancer susceptibility: a meta-analysis

Research Article

S100A10 as a novel biomarker in colorectal cancer

Research Article

Paraneoplastic hormones: parathyroid hormone-related protein (PTHrP) and erythropoietin (EPO) are related to vascular endothelial growth factor (VEGF) expression in clear cell renal cell carcinoma

Research Article

Altered expression of ERs, aromatase, and COX2 connected to estrogen action in type 1 endometrial cancer biology

Research Article

Effect of HSP90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation

Research Article

Genetic polymorphisms in glutathione S-transferases P1 (GSTP1) Ile105Val and prostate cancer risk: a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits